Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
March 22 2024 - 3:00PM
Inventiva announces the schedule of publication and presentation of
its 2023 Full-Year Financial Results
Daix (France), Long Island
City (New York, United States), March 22, 2024 – Inventiva
(Euronext Paris and Nasdaq: IVA), a clinical-stage
biopharmaceutical company focused on the development of oral small
molecule therapies for the treatment of metabolic
dysfunction-associated steatohepatitis (MASH), also known as
non-alcoholic steatohepatitis (NASH), and other diseases with
significant unmet medical needs, today announced that its
management team will host a webcast to present the Company’s 2023
full-year financial results on Thursday, March 28, 2024.
Inventiva’s 2023
full-year financial results will be published on Wednesday, March
27, 2024 at 4:00 pm (New York), 9:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of
Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of
Inventiva, and Jean Volatier, Chief Financial Officer of Inventiva,
will hold a conference call in English, followed
by a Q&A session, on Thursday, March 28, 2024,
at 8:00 am (New York), 1:00 pm
(Paris).
The conference call and the slides of the
presentation will be webcast live at:
https://edge.media-server.com/mmc/p/eh78kegs and also available on
Inventiva’s website in the “Investors – Financial results”
section.
In order to receive the conference
access information necessary to join the conference call, it is
required to register in advance using the following link:
https://register.vevent.com/register/BIca56dabf4edf46ecaaca0e735626f044.
Participants will need to use the conference access information
provided in the e-mail received at the point of registering
(dial-in number and access code).
A replay of the conference call and the
presentation will be available after the event at:
http://inventivapharma.com/investors/financial-results-presentations/.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH/NASH,
and other diseases with significant unmet medical need. The Company
benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and
epigenetic modulation. Inventiva is currently advancing one
clinical candidate, has a pipeline of two preclinical programs and
continues to explore other development opportunities to add to its
pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with MASH/NASH, a
common and progressive chronic liver disease for which there are
currently no approved therapies.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting a candidate for its Hippo signaling
pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva Pascaline ClercEVP, Strategy and
Corporate Affairsmedia@inventivapharma.com +1 202
499 8937 |
Brunswick GroupTristan Roquet Montegon /Aude
Lepreux /Julia CailleteauMedia
relationsinventiva@brunswickgroup.com +33 1 53 96 83
83 |
Westwicke, an ICR CompanyPatricia L. BankInvestor
relationspatti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
- Inventiva - PR - Webcast invitation FY 2023 - EN - 03 22
2024
Inventiva (EU:IVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Sep 2023 to Sep 2024